This is a randomized masked pilot trial of Zenapax (a humanized anti-Tac antibody) vs placebo combined with standard therapy in the treatment of the ocular complications of Behcet's disease. The primary goal of the study is to investigate the safety and efficacy of Zenapax in controlling the recurrent explosive nature of ocular manifestations in patients with Behcet's disease. Twenty patients will be randomly assigned. The primary efficacy outcomes of the study are based on the number of ocular attacks experienced and the amount of immunosuppressive medications over the 2 year study period. Secondary efficacy outcomes include the level of inflammation. This study continues to actively recruit patients. The results are monitored by the NEI Data and Safety Monitoring Committee. Since it is an ongoing masked study, there are no results to report.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Intramural Research (Z01)
Project #
1Z01EY000326-02
Application #
6432482
Study Section
(DIR)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code